| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 45 | 2024 | 184 | 9.590 |
Why?
|
| Patient Readmission | 14 | 2026 | 163 | 3.370 |
Why?
|
| Aged | 95 | 2026 | 6223 | 3.220 |
Why?
|
| Humans | 143 | 2026 | 17622 | 2.970 |
Why?
|
| Male | 103 | 2026 | 10014 | 2.930 |
Why?
|
| Patient Discharge | 11 | 2023 | 154 | 2.910 |
Why?
|
| Exercise Therapy | 13 | 2019 | 75 | 2.650 |
Why?
|
| Female | 105 | 2026 | 12715 | 2.630 |
Why?
|
| Transitional Care | 6 | 2024 | 19 | 2.620 |
Why?
|
| Heart Failure | 6 | 2026 | 414 | 2.540 |
Why?
|
| Self Care | 14 | 2017 | 144 | 2.500 |
Why?
|
| Home Care Services | 4 | 2026 | 34 | 2.350 |
Why?
|
| Quality of Life | 25 | 2022 | 505 | 2.340 |
Why?
|
| Influenza, Human | 10 | 2025 | 294 | 2.260 |
Why?
|
| Exercise | 12 | 2020 | 538 | 2.250 |
Why?
|
| Middle Aged | 71 | 2026 | 7954 | 2.230 |
Why?
|
| Internet | 14 | 2016 | 207 | 2.220 |
Why?
|
| Dyspnea | 16 | 2018 | 45 | 2.050 |
Why?
|
| Walking | 13 | 2019 | 89 | 2.040 |
Why?
|
| Hospitalization | 17 | 2026 | 831 | 2.020 |
Why?
|
| Dementia | 5 | 2024 | 136 | 1.970 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2024 | 540 | 1.940 |
Why?
|
| Aged, 80 and over | 31 | 2026 | 1976 | 1.920 |
Why?
|
| Rural Population | 6 | 2025 | 58 | 1.590 |
Why?
|
| Adult | 43 | 2026 | 7621 | 1.580 |
Why?
|
| Influenza Vaccines | 6 | 2025 | 301 | 1.560 |
Why?
|
| Antibodies, Viral | 4 | 2026 | 73 | 1.500 |
Why?
|
| United States | 33 | 2026 | 3922 | 1.460 |
Why?
|
| Retrospective Studies | 19 | 2026 | 2502 | 1.410 |
Why?
|
| Vietnam | 22 | 2022 | 42 | 1.330 |
Why?
|
| Adolescent | 28 | 2026 | 3625 | 1.300 |
Why?
|
| Telemedicine | 5 | 2024 | 196 | 1.220 |
Why?
|
| Young Adult | 22 | 2026 | 2538 | 1.220 |
Why?
|
| Health Education | 7 | 2019 | 82 | 1.200 |
Why?
|
| Anxiety | 9 | 2021 | 162 | 1.170 |
Why?
|
| Medicare | 9 | 2021 | 197 | 1.140 |
Why?
|
| Mentoring | 2 | 2019 | 29 | 1.130 |
Why?
|
| Motor Activity | 5 | 2015 | 207 | 1.110 |
Why?
|
| Social Support | 8 | 2019 | 215 | 1.090 |
Why?
|
| Depression | 11 | 2021 | 507 | 1.080 |
Why?
|
| Medicare Part C | 2 | 2023 | 11 | 1.060 |
Why?
|
| Pandemics | 4 | 2024 | 295 | 1.040 |
Why?
|
| Disease Progression | 6 | 2020 | 266 | 1.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 152 | 1.010 |
Why?
|
| Hospitals | 6 | 2022 | 71 | 0.950 |
Why?
|
| Patient Education as Topic | 7 | 2015 | 193 | 0.940 |
Why?
|
| Family Characteristics | 8 | 2026 | 70 | 0.930 |
Why?
|
| Time Factors | 12 | 2026 | 1038 | 0.910 |
Why?
|
| Metapneumovirus | 1 | 2025 | 7 | 0.910 |
Why?
|
| Paramyxoviridae Infections | 1 | 2025 | 8 | 0.910 |
Why?
|
| Prospective Studies | 19 | 2026 | 1251 | 0.900 |
Why?
|
| Health Care Costs | 4 | 2019 | 211 | 0.900 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2025 | 368 | 0.890 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 59 | 0.870 |
Why?
|
| Aftercare | 3 | 2022 | 47 | 0.860 |
Why?
|
| Child, Preschool | 14 | 2026 | 1455 | 0.840 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 52 | 0.840 |
Why?
|
| Cross-Sectional Studies | 20 | 2026 | 1295 | 0.840 |
Why?
|
| Fitness Centers | 3 | 2008 | 10 | 0.830 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 402 | 0.820 |
Why?
|
| Caregivers | 6 | 2022 | 136 | 0.820 |
Why?
|
| Palliative Care | 3 | 2021 | 54 | 0.810 |
Why?
|
| Child | 17 | 2026 | 2485 | 0.800 |
Why?
|
| Outpatients | 3 | 2021 | 103 | 0.800 |
Why?
|
| Surveys and Questionnaires | 16 | 2021 | 1296 | 0.750 |
Why?
|
| Self Report | 3 | 2020 | 262 | 0.730 |
Why?
|
| Skilled Nursing Facilities | 2 | 2021 | 6 | 0.700 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 144 | 0.700 |
Why?
|
| Risk Assessment | 6 | 2019 | 1093 | 0.700 |
Why?
|
| California | 8 | 2026 | 2433 | 0.690 |
Why?
|
| Decision Making | 2 | 2025 | 177 | 0.690 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 190 | 0.680 |
Why?
|
| Treatment Outcome | 14 | 2024 | 1161 | 0.670 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.670 |
Why?
|
| Vaccination | 8 | 2025 | 726 | 0.670 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 237 | 0.660 |
Why?
|
| Patient Transfer | 4 | 2021 | 25 | 0.650 |
Why?
|
| Monitoring, Ambulatory | 3 | 2011 | 18 | 0.650 |
Why?
|
| Employment | 1 | 2020 | 44 | 0.650 |
Why?
|
| Incidence | 6 | 2025 | 1278 | 0.630 |
Why?
|
| Infant | 9 | 2026 | 1228 | 0.610 |
Why?
|
| House Calls | 1 | 2019 | 10 | 0.610 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2019 | 7 | 0.610 |
Why?
|
| Terminal Care | 2 | 2018 | 48 | 0.610 |
Why?
|
| Seasons | 5 | 2025 | 116 | 0.600 |
Why?
|
| Severity of Illness Index | 12 | 2021 | 446 | 0.600 |
Why?
|
| Cohort Studies | 8 | 2025 | 2502 | 0.600 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2024 | 65 | 0.590 |
Why?
|
| Accelerometry | 4 | 2019 | 57 | 0.590 |
Why?
|
| Risk Factors | 13 | 2025 | 3291 | 0.580 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 1157 | 0.580 |
Why?
|
| Community Participation | 1 | 2019 | 29 | 0.570 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2025 | 21 | 0.560 |
Why?
|
| Suicide, Assisted | 1 | 2018 | 4 | 0.550 |
Why?
|
| Policy Making | 1 | 2018 | 13 | 0.550 |
Why?
|
| Terminally Ill | 1 | 2018 | 9 | 0.550 |
Why?
|
| Longitudinal Studies | 12 | 2022 | 686 | 0.550 |
Why?
|
| Cell Phone | 2 | 2009 | 9 | 0.540 |
Why?
|
| Community Health Services | 3 | 2017 | 78 | 0.540 |
Why?
|
| Cost of Illness | 4 | 2026 | 92 | 0.520 |
Why?
|
| Managed Care Programs | 3 | 2008 | 300 | 0.520 |
Why?
|
| Insurance Coverage | 1 | 2018 | 99 | 0.520 |
Why?
|
| Biomarkers | 2 | 2024 | 302 | 0.510 |
Why?
|
| Health Policy | 1 | 2018 | 106 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 135 | 0.510 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 143 | 0.500 |
Why?
|
| Pilot Projects | 9 | 2018 | 214 | 0.500 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 43 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 319 | 0.490 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2025 | 56 | 0.490 |
Why?
|
| Smartphone | 3 | 2021 | 10 | 0.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 54 | 0.490 |
Why?
|
| Activities of Daily Living | 6 | 2009 | 80 | 0.480 |
Why?
|
| Inpatients | 1 | 2016 | 78 | 0.480 |
Why?
|
| Prevalence | 12 | 2025 | 830 | 0.480 |
Why?
|
| Health Behavior | 4 | 2012 | 348 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 323 | 0.470 |
Why?
|
| Physical Fitness | 4 | 2016 | 68 | 0.460 |
Why?
|
| Self Efficacy | 6 | 2015 | 69 | 0.460 |
Why?
|
| Postural Balance | 2 | 2014 | 14 | 0.450 |
Why?
|
| Acute Disease | 2 | 2026 | 147 | 0.450 |
Why?
|
| Virus Shedding | 2 | 2026 | 2 | 0.450 |
Why?
|
| Unsafe Sex | 1 | 2015 | 18 | 0.440 |
Why?
|
| Vaccines, Inactivated | 2 | 2025 | 73 | 0.430 |
Why?
|
| Sexual and Gender Minorities | 1 | 2015 | 31 | 0.420 |
Why?
|
| Risk-Taking | 1 | 2015 | 101 | 0.420 |
Why?
|
| Child Abuse | 2 | 2018 | 45 | 0.420 |
Why?
|
| Logistic Models | 6 | 2019 | 866 | 0.410 |
Why?
|
| Case-Control Studies | 5 | 2018 | 1107 | 0.400 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 278 | 0.390 |
Why?
|
| Wisconsin | 4 | 2025 | 12 | 0.390 |
Why?
|
| Mental Health | 3 | 2014 | 163 | 0.380 |
Why?
|
| Disability Evaluation | 3 | 2014 | 45 | 0.380 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 30 | 0.370 |
Why?
|
| Patient Compliance | 2 | 2016 | 269 | 0.370 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 363 | 0.370 |
Why?
|
| Recreation | 1 | 2012 | 39 | 0.360 |
Why?
|
| Patient Selection | 3 | 2018 | 181 | 0.360 |
Why?
|
| Gait | 1 | 2011 | 8 | 0.350 |
Why?
|
| Ambulatory Care | 2 | 2026 | 228 | 0.350 |
Why?
|
| Video Games | 1 | 2011 | 9 | 0.350 |
Why?
|
| Postmenopause | 1 | 2012 | 251 | 0.340 |
Why?
|
| Nursing Informatics | 2 | 2010 | 2 | 0.340 |
Why?
|
| Affect | 3 | 2012 | 21 | 0.340 |
Why?
|
| Influenza B virus | 3 | 2025 | 13 | 0.340 |
Why?
|
| Ergometry | 1 | 2011 | 2 | 0.340 |
Why?
|
| Feedback, Psychological | 2 | 2015 | 6 | 0.340 |
Why?
|
| Faculty, Nursing | 1 | 2010 | 3 | 0.330 |
Why?
|
| Inservice Training | 1 | 2010 | 13 | 0.330 |
Why?
|
| Electronic Health Records | 3 | 2024 | 719 | 0.330 |
Why?
|
| Nursing Staff, Hospital | 2 | 2021 | 10 | 0.320 |
Why?
|
| Patient Participation | 3 | 2011 | 124 | 0.320 |
Why?
|
| Needs Assessment | 1 | 2010 | 66 | 0.320 |
Why?
|
| Advance Care Planning | 1 | 2010 | 22 | 0.320 |
Why?
|
| Veterans | 4 | 2022 | 149 | 0.320 |
Why?
|
| Regression Analysis | 3 | 2020 | 268 | 0.320 |
Why?
|
| Health Promotion | 3 | 2008 | 293 | 0.320 |
Why?
|
| Frailty | 2 | 2020 | 12 | 0.310 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 61 | 0.310 |
Why?
|
| Reinforcement (Psychology) | 1 | 2009 | 2 | 0.310 |
Why?
|
| Stress, Psychological | 2 | 2021 | 141 | 0.310 |
Why?
|
| Health Services for the Aged | 2 | 2014 | 14 | 0.310 |
Why?
|
| Sex Factors | 6 | 2016 | 599 | 0.300 |
Why?
|
| Delivery of Health Care | 4 | 2016 | 383 | 0.300 |
Why?
|
| Washington | 5 | 2019 | 388 | 0.300 |
Why?
|
| Feasibility Studies | 5 | 2018 | 107 | 0.300 |
Why?
|
| Self Concept | 1 | 2009 | 39 | 0.300 |
Why?
|
| Communication | 1 | 2010 | 181 | 0.290 |
Why?
|
| Exercise Test | 6 | 2015 | 41 | 0.290 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 603 | 0.290 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 6 | 0.290 |
Why?
|
| Insurance Benefits | 2 | 2008 | 13 | 0.290 |
Why?
|
| Patient Satisfaction | 4 | 2012 | 193 | 0.290 |
Why?
|
| Cell Culture Techniques | 2 | 2025 | 5 | 0.290 |
Why?
|
| Forced Expiratory Volume | 5 | 2017 | 66 | 0.280 |
Why?
|
| Self-Assessment | 1 | 2007 | 14 | 0.270 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 6 | 0.260 |
Why?
|
| Quality of Health Care | 2 | 2021 | 260 | 0.260 |
Why?
|
| Accidental Falls | 2 | 2020 | 50 | 0.260 |
Why?
|
| Qualitative Research | 5 | 2025 | 290 | 0.250 |
Why?
|
| Survival Rate | 3 | 2017 | 252 | 0.250 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 452 | 0.250 |
Why?
|
| Health Status | 4 | 2013 | 291 | 0.250 |
Why?
|
| Peptides | 2 | 2018 | 14 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2024 | 959 | 0.240 |
Why?
|
| Mumps virus | 1 | 2026 | 2 | 0.240 |
Why?
|
| Propensity Score | 1 | 2026 | 80 | 0.240 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 85 | 0.240 |
Why?
|
| Mumps | 1 | 2026 | 13 | 0.240 |
Why?
|
| Hand Strength | 3 | 2020 | 10 | 0.230 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2026 | 64 | 0.230 |
Why?
|
| Cough | 2 | 2015 | 20 | 0.230 |
Why?
|
| Seroepidemiologic Studies | 1 | 2025 | 19 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 7 | 0.230 |
Why?
|
| Antiviral Agents | 1 | 2026 | 85 | 0.220 |
Why?
|
| Mass Vaccination | 1 | 2005 | 22 | 0.220 |
Why?
|
| Salmonella | 1 | 2024 | 2 | 0.220 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2024 | 5 | 0.220 |
Why?
|
| Shigella | 1 | 2024 | 2 | 0.220 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 6 | 0.220 |
Why?
|
| Chickenpox | 1 | 2005 | 35 | 0.220 |
Why?
|
| Pain | 3 | 2024 | 75 | 0.220 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2024 | 8 | 0.210 |
Why?
|
| Antigens, Viral | 1 | 2024 | 4 | 0.210 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 40 | 0.210 |
Why?
|
| Cardiac Rehabilitation | 1 | 2004 | 6 | 0.210 |
Why?
|
| Fatigue | 3 | 2024 | 30 | 0.210 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 91 | 0.210 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 28 | 0.210 |
Why?
|
| Quality Improvement | 2 | 2016 | 189 | 0.210 |
Why?
|
| Interleukin-8 | 1 | 2024 | 4 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 308 | 0.210 |
Why?
|
| Hyperkalemia | 1 | 2024 | 15 | 0.210 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 114 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 527 | 0.200 |
Why?
|
| Frail Elderly | 2 | 2020 | 8 | 0.200 |
Why?
|
| Family | 2 | 2021 | 111 | 0.190 |
Why?
|
| Registries | 3 | 2018 | 475 | 0.190 |
Why?
|
| Walk Test | 2 | 2019 | 6 | 0.190 |
Why?
|
| Suicidal Ideation | 2 | 2014 | 99 | 0.180 |
Why?
|
| Brain Concussion | 1 | 2022 | 1 | 0.180 |
Why?
|
| Age Factors | 3 | 2016 | 874 | 0.180 |
Why?
|
| Prognosis | 4 | 2019 | 609 | 0.180 |
Why?
|
| Military Personnel | 1 | 2022 | 12 | 0.180 |
Why?
|
| Motivation | 3 | 2021 | 112 | 0.180 |
Why?
|
| Interviews as Topic | 2 | 2025 | 324 | 0.180 |
Why?
|
| Outcome Assessment (Health Care) | 4 | 2015 | 213 | 0.180 |
Why?
|
| Comorbidity | 4 | 2022 | 552 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 380 | 0.170 |
Why?
|
| HIV Infections | 2 | 2018 | 584 | 0.170 |
Why?
|
| Bayes Theorem | 3 | 2026 | 73 | 0.170 |
Why?
|
| Fear | 1 | 2021 | 14 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 73 | 0.170 |
Why?
|
| Monitoring, Physiologic | 2 | 2015 | 35 | 0.170 |
Why?
|
| Work Engagement | 1 | 2021 | 2 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 702 | 0.170 |
Why?
|
| Primary Health Care | 2 | 2024 | 729 | 0.160 |
Why?
|
| Yoga | 2 | 2012 | 25 | 0.160 |
Why?
|
| Walking Speed | 1 | 2020 | 3 | 0.160 |
Why?
|
| Health Personnel | 2 | 2019 | 135 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 204 | 0.160 |
Why?
|
| Telephone | 1 | 2021 | 159 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 11 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 42 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 36 | 0.160 |
Why?
|
| Inflammation | 2 | 2018 | 60 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2020 | 214 | 0.150 |
Why?
|
| Telomere | 1 | 2019 | 18 | 0.150 |
Why?
|
| Independent Living | 1 | 2019 | 24 | 0.150 |
Why?
|
| Geriatric Nursing | 1 | 2019 | 3 | 0.150 |
Why?
|
| Attitude to Death | 1 | 2019 | 7 | 0.150 |
Why?
|
| Chronic Pain | 1 | 2021 | 133 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2016 | 107 | 0.150 |
Why?
|
| Occupational Stress | 1 | 2019 | 3 | 0.150 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 10 | 0.150 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 3 | 2005 | 3 | 0.150 |
Why?
|
| Oregon | 1 | 2019 | 172 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 2019 | 38 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 117 | 0.150 |
Why?
|
| Bronchodilator Agents | 2 | 2016 | 22 | 0.150 |
Why?
|
| State Medicine | 1 | 2018 | 5 | 0.150 |
Why?
|
| Spouses | 1 | 2019 | 9 | 0.150 |
Why?
|
| Reference Values | 3 | 2007 | 86 | 0.140 |
Why?
|
| Papillomaviridae | 1 | 2019 | 61 | 0.140 |
Why?
|
| Spirometry | 2 | 2015 | 59 | 0.140 |
Why?
|
| Singing | 1 | 2018 | 1 | 0.140 |
Why?
|
| Cyclohexylamines | 1 | 2018 | 1 | 0.140 |
Why?
|
| Ornithine | 1 | 2018 | 1 | 0.140 |
Why?
|
| Personal Autonomy | 1 | 2018 | 6 | 0.140 |
Why?
|
| Psychotherapy | 1 | 2018 | 56 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 10 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 25 | 0.130 |
Why?
|
| Actigraphy | 3 | 2015 | 14 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2018 | 74 | 0.130 |
Why?
|
| Environment Design | 2 | 2020 | 67 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 60 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 27 | 0.130 |
Why?
|
| Abbreviated Injury Scale | 1 | 2016 | 1 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2016 | 9 | 0.130 |
Why?
|
| Trauma Centers | 1 | 2016 | 6 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2018 | 147 | 0.130 |
Why?
|
| Psychology, Adolescent | 1 | 2016 | 11 | 0.130 |
Why?
|
| Learning | 1 | 2016 | 18 | 0.120 |
Why?
|
| Medical Overuse | 1 | 2016 | 14 | 0.120 |
Why?
|
| Violence | 1 | 2016 | 33 | 0.120 |
Why?
|
| Sinusitis | 1 | 2016 | 18 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 25 | 0.120 |
Why?
|
| Metered Dose Inhalers | 1 | 2016 | 4 | 0.120 |
Why?
|
| Prescription Drug Overuse | 1 | 2016 | 4 | 0.120 |
Why?
|
| Age Distribution | 2 | 2015 | 230 | 0.120 |
Why?
|
| Students | 1 | 2016 | 49 | 0.120 |
Why?
|
| Lung | 1 | 2016 | 57 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2016 | 33 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 95 | 0.120 |
Why?
|
| Length of Stay | 1 | 2016 | 182 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 187 | 0.120 |
Why?
|
| Self-Management | 1 | 2016 | 27 | 0.120 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2015 | 19 | 0.120 |
Why?
|
| Research Report | 1 | 2015 | 23 | 0.120 |
Why?
|
| Public Sector | 1 | 2015 | 7 | 0.120 |
Why?
|
| Research | 2 | 2016 | 60 | 0.120 |
Why?
|
| Habits | 1 | 2015 | 6 | 0.120 |
Why?
|
| Somatoform Disorders | 1 | 2015 | 6 | 0.110 |
Why?
|
| Tics | 1 | 2015 | 3 | 0.110 |
Why?
|
| Capacity Building | 1 | 2015 | 11 | 0.110 |
Why?
|
| Health Services Research | 1 | 2016 | 201 | 0.110 |
Why?
|
| Diazomethane | 1 | 2015 | 1 | 0.110 |
Why?
|
| Methionine | 1 | 2015 | 5 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 2 | 2026 | 13 | 0.110 |
Why?
|
| Smoking | 1 | 2017 | 420 | 0.110 |
Why?
|
| Child Abuse, Sexual | 2 | 2018 | 13 | 0.110 |
Why?
|
| Immunization, Secondary | 2 | 2026 | 58 | 0.110 |
Why?
|
| Respiratory Function Tests | 2 | 2012 | 31 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2016 | 24 | 0.110 |
Why?
|
| Residence Characteristics | 2 | 2016 | 256 | 0.110 |
Why?
|
| Antibody Formation | 2 | 2024 | 7 | 0.110 |
Why?
|
| Research Design | 4 | 2018 | 337 | 0.100 |
Why?
|
| Hospice Care | 1 | 2013 | 9 | 0.100 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 12 | 0.100 |
Why?
|
| Physical Endurance | 1 | 2012 | 4 | 0.100 |
Why?
|
| Pain Management | 1 | 2013 | 58 | 0.090 |
Why?
|
| Vital Capacity | 1 | 2012 | 33 | 0.090 |
Why?
|
| Focus Groups | 3 | 2018 | 144 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2016 | 398 | 0.090 |
Why?
|
| Guanylate Cyclase | 2 | 2002 | 2 | 0.090 |
Why?
|
| Expert Testimony | 1 | 2011 | 5 | 0.090 |
Why?
|
| Geriatrics | 1 | 2011 | 5 | 0.090 |
Why?
|
| Observational Studies as Topic | 2 | 2024 | 46 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 302 | 0.090 |
Why?
|
| Patient Simulation | 1 | 2010 | 1 | 0.080 |
Why?
|
| Telenursing | 1 | 2010 | 1 | 0.080 |
Why?
|
| Manikins | 1 | 2010 | 2 | 0.080 |
Why?
|
| Research Personnel | 2 | 2021 | 28 | 0.080 |
Why?
|
| Education, Distance | 1 | 2010 | 5 | 0.080 |
Why?
|
| Psychometrics | 2 | 2021 | 119 | 0.080 |
Why?
|
| Factor Analysis, Statistical | 2 | 2018 | 35 | 0.080 |
Why?
|
| Attitude to Computers | 1 | 2010 | 13 | 0.080 |
Why?
|
| Life Style | 1 | 2012 | 321 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 70 | 0.080 |
Why?
|
| Aging | 1 | 2011 | 159 | 0.080 |
Why?
|
| Family Relations | 1 | 2009 | 16 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2009 | 22 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2012 | 276 | 0.070 |
Why?
|
| Health Surveys | 3 | 2016 | 242 | 0.070 |
Why?
|
| Cost Savings | 1 | 2007 | 20 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 228 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2018 | 4 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 2 | 2018 | 59 | 0.060 |
Why?
|
| Consumer Behavior | 1 | 2007 | 28 | 0.060 |
Why?
|
| Antibody Affinity | 1 | 2026 | 1 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2026 | 35 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2005 | 14 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2026 | 84 | 0.060 |
Why?
|
| Genotype | 1 | 2026 | 224 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 37 | 0.060 |
Why?
|
| Contact Tracing | 1 | 2025 | 2 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 1 | 0.060 |
Why?
|
| Tyrosine | 1 | 2005 | 2 | 0.060 |
Why?
|
| Minnesota | 1 | 2025 | 51 | 0.060 |
Why?
|
| Measles | 1 | 2005 | 24 | 0.060 |
Why?
|
| Basic Reproduction Number | 1 | 2025 | 1 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 173 | 0.060 |
Why?
|
| Health Maintenance Organizations | 1 | 2007 | 403 | 0.060 |
Why?
|
| Tennessee | 1 | 2024 | 6 | 0.060 |
Why?
|
| Access to Information | 1 | 2005 | 12 | 0.050 |
Why?
|
| Linear Models | 2 | 2016 | 204 | 0.050 |
Why?
|
| Urban Population | 1 | 2025 | 111 | 0.050 |
Why?
|
| Computers, Handheld | 1 | 2024 | 10 | 0.050 |
Why?
|
| Eggs | 1 | 2024 | 8 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2024 | 21 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 14 | 0.050 |
Why?
|
| Mortality | 1 | 2005 | 116 | 0.050 |
Why?
|
| Spironolactone | 1 | 2024 | 7 | 0.050 |
Why?
|
| Cause of Death | 1 | 2005 | 179 | 0.050 |
Why?
|
| Peer Group | 1 | 2004 | 55 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 56 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 1 | 0.050 |
Why?
|
| Online Systems | 1 | 2003 | 7 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2024 | 109 | 0.050 |
Why?
|
| Continental Population Groups | 2 | 2016 | 283 | 0.050 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 2 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 80 | 0.040 |
Why?
|
| Nurses | 1 | 2021 | 33 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 121 | 0.040 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 34 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 54 | 0.040 |
Why?
|
| Health Priorities | 1 | 2020 | 24 | 0.040 |
Why?
|
| Kinetics | 2 | 2015 | 12 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 166 | 0.040 |
Why?
|
| Health Resources | 1 | 2018 | 39 | 0.040 |
Why?
|
| Scotland | 1 | 2018 | 3 | 0.030 |
Why?
|
| Physical Abuse | 1 | 2018 | 2 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 821 | 0.030 |
Why?
|
| Respiration | 1 | 2018 | 6 | 0.030 |
Why?
|
| Electrons | 1 | 2018 | 1 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2018 | 2 | 0.030 |
Why?
|
| Hydrogen | 1 | 2018 | 3 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 6 | 0.030 |
Why?
|
| Memory | 1 | 2018 | 13 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 12 | 0.030 |
Why?
|
| Amino Acids | 1 | 2018 | 5 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 34 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2018 | 33 | 0.030 |
Why?
|
| Bortezomib | 1 | 2017 | 1 | 0.030 |
Why?
|
| Melphalan | 1 | 2017 | 2 | 0.030 |
Why?
|
| Prednisone | 1 | 2017 | 6 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 19 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 55 | 0.030 |
Why?
|
| Infection | 1 | 2017 | 17 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 120 | 0.030 |
Why?
|
| Cognition | 1 | 2018 | 91 | 0.030 |
Why?
|
| Time | 1 | 2016 | 20 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2016 | 12 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 19 | 0.030 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 5 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 39 | 0.030 |
Why?
|
| Nuclear Family | 1 | 2015 | 7 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2015 | 40 | 0.030 |
Why?
|
| Medical Assistance | 1 | 2015 | 7 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 28 | 0.030 |
Why?
|
| Photolysis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 6 | 0.030 |
Why?
|
| Minority Groups | 1 | 2016 | 104 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 631 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2015 | 108 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 144 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2005 | 2 | 0.030 |
Why?
|
| Protein Transport | 2 | 2005 | 4 | 0.030 |
Why?
|
| Cell Line | 2 | 2005 | 11 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 346 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 232 | 0.020 |
Why?
|
| Americas | 1 | 2013 | 2 | 0.020 |
Why?
|
| Northwestern United States | 1 | 2013 | 53 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2016 | 443 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 177 | 0.020 |
Why?
|
| Transfection | 2 | 2002 | 5 | 0.020 |
Why?
|
| Loneliness | 1 | 2012 | 10 | 0.020 |
Why?
|
| Consensus | 1 | 2011 | 41 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 11 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2009 | 11 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 13 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 88 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 42 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 457 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2005 | 6 | 0.010 |
Why?
|
| Immunity, Herd | 1 | 2005 | 4 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 37 | 0.010 |
Why?
|
| Measles Vaccine | 1 | 2005 | 17 | 0.010 |
Why?
|
| Transportation | 1 | 2005 | 14 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2005 | 40 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2005 | 25 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 1 | 0.010 |
Why?
|
| Schools | 1 | 2005 | 91 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 133 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 842 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 2002 | 1 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2002 | 2 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 5 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 14 | 0.010 |
Why?
|
| Autopsy | 1 | 2002 | 16 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 33 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 1 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 2 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 6 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 10 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 33 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 17 | 0.010 |
Why?
|
| Temperature | 1 | 2001 | 17 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 27 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 122 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 285 | 0.010 |
Why?
|